



Clinical trial results:

A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with non-small cell lung cancer

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2012-003383-51 |
| Trial protocol | GB |
| Global end of trial date | 05 April 2019 |

Results information

| | |
|-----------------------------------|---|
| Result version number | v1 (current) |
| This version publication date | 02 March 2020 |
| First version publication date | 02 March 2020 |
| Summary attachment (see zip file) | Final statistical analysis report (PIN final analysis report version 1 FINAL dated 14022020.docx) |

Trial information

Trial identification

| | |
|-----------------------|---------------|
| Sponsor protocol code | 2012/VCC/0037 |
|-----------------------|---------------|

Additional study identifiers

| | |
|------------------------------------|----------------|
| ISRCTN number | ISRCTN42518913 |
| ClinicalTrials.gov id (NCT number) | NCT01788332 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Velindre NHS Trust |
| Sponsor organisation address | Unit 2 Charnwood Court Heol Billingsley, , Parc Nantgarw, Cardiff , United Kingdom, CF15 7QZ |
| Public contact | Georgina Gardner, Centre for Trials Research, 0044 2920687581, pin@cardiff.ac.uk |
| Scientific contact | Angela Casbard, Centre for Trials Research, 0044 2920687470, CasbardAC@cardiff.ac.uk |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 10 February 2020 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 22 February 2019 |
| Global end of trial reached? | Yes |
| Global end of trial date | 05 April 2019 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The main objective of this trial is to establish whether treatment with Olaparib in NSCLC patients who have already responded to induction chemotherapy delays disease progression compared to placebo.

Protection of trial subjects:

NA

Background therapy:

NA

Evidence for comparator:

Placebo

| | |
|---|--------------|
| Actual start date of recruitment | 22 July 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects**Subjects enrolled per country**

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United Kingdom: 70 |
| Worldwide total number of subjects | 70 |
| EEA total number of subjects | 70 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 38 |
| From 65 to 84 years | 32 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

70 patients were randomised from 23 UK centres between August 2014 and November 2017.

Pre-assignment

Screening details:

Screening criteria are listed in the protocol Section 6.2. 264 were assessed for eligibility for randomisation. 139 were not eligible and 55 were eligible but not randomised.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Baseline |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Placebo

| | |
|--|----------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

300mg bd administered and reviewed in 21-day cycles until disease progression, unacceptable toxicity or patient withdrawal of consent.

| | |
|------------------|----------|
| Arm title | Olaparib |
|------------------|----------|

Arm description:

Olaparib

300mg po bd q21 until disease progression

| | |
|--|--------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Olaparib |
| Investigational medicinal product code | Olaparib (AZD2281, KU-0059436) |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

300mg bd administered and reviewed in 21-day cycles until disease progression, unacceptable toxicity or patient withdrawal of consent.

| Number of subjects in period 1 | Placebo | Olaparib |
|--------------------------------|---------|----------|
| Started | 38 | 32 |
| Completed | 38 | 32 |

Period 2

| | |
|------------------------------|--------------------------------|
| Period 2 title | Treatment and follow up |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Placebo

| | |
|--|----------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

300mg bd administered and reviewed in 21-day cycles until disease progression, unacceptable toxicity or patient withdrawal of consent.

| | |
|------------------|----------|
| Arm title | Olaparib |
|------------------|----------|

Arm description:

Olaparib

300mg po bd q21 until disease progression

| | |
|--|--------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Olaparib |
| Investigational medicinal product code | Olaparib (AZD2281, KU-0059436) |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

300mg bd administered and reviewed in 21-day cycles until disease progression, unacceptable toxicity or patient withdrawal of consent.

| Number of subjects in period 2 | Placebo | Olaparib |
|---------------------------------------|---------|----------|
| Started | 38 | 32 |
| Completed | 38 | 31 |
| Not completed | 0 | 1 |
| Found to be ineligible | - | 1 |

Baseline characteristics

Reporting groups

| | |
|---|----------|
| Reporting group title | Placebo |
| Reporting group description: | |
| Placebo | |
| Reporting group title | Olaparib |
| Reporting group description: | |
| Olaparib 300mg po bd q21 until disease progression | |

| Reporting group values | Placebo | Olaparib | Total |
|---|--------------|--------------|-------|
| Number of subjects | 38 | 32 | 70 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | | | 0 |
| Preterm newborn infants (gestational age < 37 wks) | | | 0 |
| Newborns (0-27 days) | | | 0 |
| Infants and toddlers (28 days-23 months) | | | 0 |
| Children (2-11 years) | | | 0 |
| Adolescents (12-17 years) | | | 0 |
| Adults (18-64 years) | | | 0 |
| From 65-84 years | | | 0 |
| 85 years and over | | | 0 |
| Age continuous | | | |
| Units: years | | | |
| median | 63.3 | 64.7 | |
| inter-quartile range (Q1-Q3) | 58.6 to 69.9 | 60.5 to 71.5 | - |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 14 | 16 | 30 |
| Male | 24 | 16 | 40 |
| Non-small cell lung cancer type | | | |
| Units: Subjects | | | |
| Adenocarcinoma | 18 | 19 | 37 |
| Squamous | 18 | 13 | 31 |
| Large cell nos | 1 | 0 | 1 |
| Mixed adenocarcinoma/Squamous | 1 | 0 | 1 |
| T stage | | | |
| Units: Subjects | | | |
| T1 | 2 | 3 | 5 |
| T2 | 3 | 6 | 9 |
| T3 | 6 | 10 | 16 |
| T4 | 23 | 12 | 35 |
| TX | 3 | 0 | 3 |
| Missing | 1 | 1 | 2 |
| N stage | | | |

| | | | |
|--|----|----|----|
| Units: Subjects | | | |
| N0 | 2 | 6 | 8 |
| N1 | 3 | 1 | 4 |
| N2 | 16 | 9 | 25 |
| N3 | 15 | 13 | 28 |
| NX | 1 | 2 | 3 |
| Missing | 1 | 1 | 2 |
| M stage | | | |
| Units: Subjects | | | |
| M0 | 10 | 10 | 20 |
| M1a | 15 | 10 | 25 |
| M1b | 13 | 11 | 24 |
| Missing | 0 | 1 | 1 |
| Stage of NSCLC | | | |
| Units: Subjects | | | |
| IIIB | 13 | 10 | 23 |
| IV | 25 | 22 | 47 |
| Sites affected | | | |
| Units: Subjects | | | |
| Adrenal gland | 0 | 1 | 1 |
| Bone metastases | 4 | 2 | 6 |
| Brain metastases | 1 | 0 | 1 |
| Chest wall; lung metastases | 0 | 1 | 1 |
| Chest wall; Mediastinum | 1 | 0 | 1 |
| Chest wall; Trachea | 0 | 1 | 1 |
| Chest wall; Trachea; Lung metastases | 1 | 0 | 1 |
| Heart pericardium; Bone metastases; Brain metastases | 0 | 1 | 1 |
| Heart pericardium; Lung metastases | 1 | 0 | 1 |
| Ipsilateral hilar, Mediastinal and supraclavicular | 0 | 1 | 1 |
| Left hilar region | 1 | 0 | 1 |
| Left lower lobe of bronchus | 1 | 0 | 1 |
| Liver metastases; Adrenal gland | 1 | 1 | 2 |
| Liver metastases; Bone metastases | 1 | 2 | 3 |
| Liver metastases; Lung metastases | 1 | 0 | 1 |
| Lung metastases | 7 | 2 | 9 |
| Lung metastases; Adrenal gland; Mediastinum | 0 | 1 | 1 |
| Lung metastases; Mediastinum | 0 | 1 | 1 |
| Lung metastases; Primary Mass | 0 | 1 | 1 |
| Lung metastases; Retroperitoneal | 1 | 0 | 1 |
| Lung metastases; side neck nodes | 1 | 0 | 1 |
| Lung metastases; sub aortic lymph node; para aorti | 1 | 0 | 1 |
| Lung; lymph node | 1 | 0 | 1 |
| Lymph nodes | 1 | 0 | 1 |
| None | 2 | 5 | 7 |
| Oesophagus; Pleura; Liver metastases | 0 | 1 | 1 |
| Oesophagus; Trachea | 1 | 0 | 1 |
| Pericardial effusion | 1 | 0 | 1 |

| | | | |
|---|----|----|----|
| Pleura | 0 | 1 | 1 |
| Pleura; Bone metastases | 1 | 0 | 1 |
| Pleura; Heart pericardium; Pulmonary Artery; Right | 1 | 0 | 1 |
| Pleura; Liver metastases; Lung metastases; Bone me | 0 | 1 | 1 |
| Pleura; Lung metastases | 1 | 2 | 3 |
| Pleura; Lymph node | 0 | 1 | 1 |
| Pleura; Regional nodes; Distant nodes. | 0 | 1 | 1 |
| Right upper lobe | 3 | 1 | 4 |
| Rib | 0 | 1 | 1 |
| RIGHT HILAR LESION | 0 | 1 | 1 |
| Right Neck Lymph Nodes | 1 | 0 | 1 |
| Right upper lobe; mediastinal lymphadenopathy | 0 | 1 | 1 |
| Spleen | 1 | 0 | 1 |
| Trachea; Adrenal gland | 1 | 0 | 1 |
| Trachea; Lung metastases; right hilar | 0 | 1 | 1 |
| Type of induction chemotherapy Units: Subjects | | | |
| Carboplatin | 1 | 0 | 1 |
| Carboplatin; Vinorelbine | 3 | 1 | 4 |
| Cisplatin | 0 | 1 | 1 |
| Cisplatin; Carboplatin | 1 | 0 | 1 |
| Cisplatin; Pemetrexed | 5 | 4 | 9 |
| Cisplatin; Vinorelbine | 1 | 1 | 2 |
| Gemcitabine | 2 | 3 | 5 |
| Gemcitabine; Carboplatin | 11 | 6 | 17 |
| Gemcitabine; Docetaxel | 1 | 0 | 1 |
| Gemcitabine; Pemetrexed | 0 | 1 | 1 |
| Not known | 1 | 3 | 4 |
| Paclitaxel | 0 | 1 | 1 |
| Pemetrexed | 5 | 3 | 8 |
| Pemetrexed; Carboplatin | 7 | 8 | 15 |
| Response to induction chemotherapy Units: Subjects | | | |
| Complete response | 1 | 2 | 3 |
| Partial response | 34 | 28 | 62 |
| Other evidence of tumour shrinkage/Mixed stable | 3 | 2 | 5 |
| Smoking history Units: Subjects | | | |
| Never smoked | 3 | 3 | 6 |
| Ever smoked | 35 | 29 | 64 |
| ECOG status Units: Subjects | | | |
| Zero | 13 | 9 | 22 |
| One | 25 | 23 | 48 |
| Site of target tumour Units: Subjects | | | |
| Anterior mediastinal mass; Left anterior lung mass | 0 | 1 | 1 |

| | | | |
|--|---|---|---|
| Aortopulmonary soft tissue mass; Splenic lesion | 1 | 0 | 1 |
| Apical segment, posteriorly right lower lobe; righ | 0 | 1 | 1 |
| Central left lung mass; paracardiac chest wall mas | 1 | 0 | 1 |
| Left Adrenal; Left Hilum | 0 | 1 | 1 |
| Left basal; Liver mets | 1 | 0 | 1 |
| Left hilar mass | 2 | 1 | 3 |
| Left hilar; left upper lobe mass | 1 | 0 | 1 |
| Left lower lobe | 0 | 1 | 1 |
| Left lung | 1 | 2 | 3 |
| Left lung; liver | 1 | 1 | 2 |
| LEFT PERIHILAR LUNG LESION; SUBCARINAL LYMPH NODE | 1 | 0 | 1 |
| LEFT PERIHILAR MASS; RIGHT UPPER LOBE LESION | 1 | 0 | 1 |
| Left posterior lower zone; Left anterior upper zon | 1 | 0 | 1 |
| Left supraclavicular region; right lung base | 0 | 1 | 1 |
| Left upper lobe | 4 | 2 | 6 |
| Left upper lobe; Apical left lower lobe metastases | 1 | 0 | 1 |
| Left upper lobe; Apical right lower lobe | 0 | 1 | 1 |
| Left upper lobe; left hilar | 1 | 1 | 2 |
| Left upper lobe; liver | 0 | 1 | 1 |
| Left upper lobe; right hilar | 1 | 0 | 1 |
| Low right paratrachael / precarninal node; Subcari | 1 | 0 | 1 |
| Mediastinal mass | 1 | 0 | 1 |
| Not known | 2 | 2 | 4 |
| Pleural deposit adjacent to aortic arch; Pleural d | 1 | 0 | 1 |
| POSTERIOR RIGHT PERIHILAR LUNG LESION; ANTERIOR RI | 0 | 1 | 1 |
| Right apical lower lobe; Left upper lobe mass | 0 | 1 | 1 |
| RIGHT HILAR ANTERIOR; RIGHT HILAR POSTERIOR | 0 | 1 | 1 |
| RIGHT HILAR LESION; RIGHT UPPER POLE RENAL LESION | 0 | 1 | 1 |
| Right Hilar Mass; Pretracheal | 1 | 0 | 1 |
| Right hilar mass; right adrenal mass | 1 | 0 | 1 |
| Right lower lobe | 1 | 3 | 4 |
| RIGHT LOWER LOBE CAVITY; CONGLOMERATE OF MEDIASTIN | 1 | 0 | 1 |
| Right paratracheal lymph node | 0 | 1 | 1 |
| Right peri hilar mass | 1 | 0 | 1 |
| Right upper lobe | 6 | 3 | 9 |
| RIGHT UPPER LOBE LUNG LESION; RIGHT OBLIQUE FISSUR | 0 | 1 | 1 |
| Right upper lobe; left adrenal gland | 0 | 1 | 1 |
| Right upper lobe; Right lower paratracheal lymph n | 1 | 0 | 1 |

| | | | |
|---|----------------|----------------|---|
| Rt Paratracheal LN; Right upper lobe | 0 | 1 | 1 |
| SEGMENT 5; INFERIOR TIP | 0 | 1 | 1 |
| Soft tissue anterior; subcarinal node | 1 | 0 | 1 |
| Sub pleural left lung lesion | 0 | 1 | 1 |
| Subcarinal node | 1 | 0 | 1 |
| Sub-carinal node; Right hilar node | 1 | 0 | 1 |
| Number of cycles of induction chemotherapy Units: Number | | | |
| median | 4 | 4 | |
| inter-quartile range (Q1-Q3) | 4 to 4 | 4 to 4 | - |
| Systolic blood pressure Units: mmHg | | | |
| median | 132 | 133 | |
| inter-quartile range (Q1-Q3) | 124 to 146 | 123.5 to 150 | - |
| Diastolic blood pressure Units: mmHg | | | |
| median | 76.5 | 73.5 | |
| inter-quartile range (Q1-Q3) | 73.0 to 87.0 | 69.5 to 86.5 | - |
| Oxygen saturation Units: percentage | | | |
| median | 97 | 97.5 | |
| inter-quartile range (Q1-Q3) | 96 to 98 | 97 to 98 | - |
| Pulse Units: Bpm | | | |
| median | 86.0 | 80.0 | |
| inter-quartile range (Q1-Q3) | 77.0 to 95.0 | 74.0 to 88.5 | - |
| Weight Units: kg | | | |
| median | 74.9 | 75.7 | |
| inter-quartile range (Q1-Q3) | 62.3 to 93.8 | 63.3 to 83.6 | - |
| ECG Resting QTc Units: msec | | | |
| median | 431.0 | 425.5 | |
| inter-quartile range (Q1-Q3) | 417.0 to 445.0 | 413.0 to 439.0 | - |
| Longest diameter of tumours: Primary Units: mm | | | |
| median | 39.5 | 29.5 | |
| inter-quartile range (Q1-Q3) | 24.0 to 55.5 | 15.0 to 40.0 | - |
| Longest diameter of tumours: Lymph node Units: mm | | | |
| median | 16.0 | 16.5 | |
| inter-quartile range (Q1-Q3) | 10.0 to 19.0 | 13.5 to 19.0 | - |
| Longest diameter of tumours: Liver Units: mm | | | |
| median | 26.0 | 14.0 | |
| inter-quartile range (Q1-Q3) | 26.0 to 26.0 | 14.0 to 14.0 | - |
| Longest diameter of tumours: Adrenal glands Units: mm | | | |

| | | | |
|--|----------------------|----------------------|---|
| median inter-quartile range (Q1-Q3) | 15.5 11.0 to 20.0 | 47.5 36.0 to 59.0 | - |
| Longest diameter of tumours: Other Units: mm median inter-quartile range (Q1-Q3) | 35.0 24.5 to 46.0 | 34.5 30.0 to 39.0 | - |
| Target tumours: Sum of longest diameters Units: mm median inter-quartile range (Q1-Q3) | 44.5 33.0 to 62.5 | 53.5 30.0 to 69.0 | - |

End points

End points reporting groups

| | |
|---|----------|
| Reporting group title | Placebo |
| Reporting group description: Placebo | |
| Reporting group title | Olaparib |
| Reporting group description: Olaparib 300mg po bd q21 until disease progression | |
| Reporting group title | Placebo |
| Reporting group description: Placebo | |
| Reporting group title | Olaparib |
| Reporting group description: Olaparib 300mg po bd q21 until disease progression | |

Primary: Progression-free survival

| | |
|---|---------------------------|
| End point title | Progression-free survival |
| End point description: | |
| End point type | Primary |
| End point timeframe: From date of randomisation to date of disease progression or death, whichever comes first | |

| End point values | Placebo | Olaparib | | |
|---------------------------------------|--------------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 38 | 32 | | |
| Units: weeks | | | | |
| median (inter-quartile range (Q1-Q3)) | 12.0 (5.6 to 18.7) | 16.6 (7.1 to 21.7) | | |

Statistical analyses

| | |
|--|--------------------|
| Statistical analysis title | PFS unadjusted |
| Statistical analysis description: Unadjusted analysis | |
| Comparison groups | Placebo v Olaparib |

| | |
|---|-----------------------|
| Number of subjects included in analysis | 70 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.23 ^[1] |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.83 |
| Confidence interval | |
| level | Other: 80 % |
| sides | 2-sided |
| lower limit | 0.6 |
| upper limit | 1.15 |

Notes:

[1] - Sample size calculation based on 80% power and a one-sided α (type I error) of 0.2. Result not statistically significant.

| | |
|--|-----------------------|
| Statistical analysis title | PFS adjusted |
| Statistical analysis description: | |
| Adjusted for smoking history and histology | |
| Comparison groups | Placebo v Olaparib |
| Number of subjects included in analysis | 70 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.11 ^[2] |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.73 |
| Confidence interval | |
| level | Other: 80 % |
| sides | 2-sided |
| lower limit | 0.52 |
| upper limit | 1.02 |

Notes:

[2] - Sample size calculation based on 80% power and a one-sided α (type I error) of 0.2. Result statistically significant.

Secondary: Overall survival

| | |
|--|------------------|
| End point title | Overall survival |
| End point description: | |
| | |
| End point type | Secondary |
| End point timeframe: | |
| Measured from date of randomisation to date of death, with those still alive censored at date last seen. | |

| End point values | Placebo | Olaparib | | |
|---------------------------------------|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 38 | 32 | | |
| Units: weeks | | | | |
| median (inter-quartile range (Q1-Q3)) | 31.3 (22.4 to 58.6) | 59.4 (38.7 to 67.9) | | |

Statistical analyses

| Statistical analysis title | Overall survival |
|---|-----------------------|
| Comparison groups | Placebo v Olaparib |
| Number of subjects included in analysis | 70 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence |
| P-value | = 0.22 ^[3] |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.68 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.37 |
| upper limit | 1.26 |

Notes:

[3] - Two-sided p-value

Secondary: Objective response rate

| End point title | Objective response rate |
|---|-------------------------|
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| From date of randomisation to RECIST assessment at 6 weeks post randomisation (end of Cycle 2). | |

| End point values | Placebo | Olaparib | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 38 | 32 | | |
| Units: Subjects | | | | |
| number (not applicable) | | | | |
| Complete response | 0 | 0 | | |
| Partial response | 1 | 0 | | |
| Stable disease | 22 | 20 | | |
| Progressive disease | 12 | 7 | | |
| Not evaluable | 0 | 1 | | |
| RECIST assessment not done | 0 | 1 | | |

| | | | | |
|---|---|---|--|--|
| Did not reach end of cycle 2 RECIST timepoint | 3 | 3 | | |
|---|---|---|--|--|

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From baseline screening assessments to disease progression or death (whichever comes first) or if still alive and not progressed date data collection ended.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|-------|
| Dictionary name | CTCAE |
|-----------------|-------|

| | |
|--------------------|------|
| Dictionary version | 4.03 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description: -

| | |
|-----------------------|----------|
| Reporting group title | Olaparib |
|-----------------------|----------|

Reporting group description: -

| Serious adverse events | Placebo | Olaparib | |
|---|------------------|-----------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 10 / 38 (26.32%) | 9 / 31 (29.03%) | |
| number of deaths (all causes) | 25 | 18 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Pathological fracture imminent | | | |
| alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 0 / 38 (0.00%) | 1 / 31 (3.23%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Pericardial effusion | | | |
| alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 1 / 38 (2.63%) | 0 / 31 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Headache | | | |
| alternative dictionary used: MedDRA 19 | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 1 / 38 (2.63%) | 1 / 31 (3.23%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lethargy | | | |
| alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 0 / 38 (0.00%) | 1 / 31 (3.23%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 1 / 38 (2.63%) | 0 / 31 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nausea | | | |
| alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 0 / 38 (0.00%) | 1 / 31 (3.23%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Dysphagia | | | |
| alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 0 / 38 (0.00%) | 1 / 31 (3.23%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Device occlusion | | | |
| alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 1 / 38 (2.63%) | 0 / 31 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnea | | | |
| alternative dictionary used: MedDRA 19 | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 2 / 38 (5.26%) | 1 / 31 (3.23%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reaspiratory tract haemorrhage alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 1 / 38 (2.63%) | 0 / 31 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders Suicide attempt alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 1 / 38 (2.63%) | 0 / 31 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders Back pain alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 0 / 38 (0.00%) | 1 / 31 (3.23%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations Lung infection alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 2 / 38 (5.26%) | 0 / 31 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin infection alternative dictionary used: MedDRA 19 | | | |
| subjects affected / exposed | 0 / 38 (0.00%) | 1 / 31 (3.23%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| Non-serious adverse events | Placebo | Olaparib | |
|---|-------------------|-------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 38 / 38 (100.00%) | 31 / 31 (100.00%) | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 9 / 38 (23.68%) | 3 / 31 (9.68%) | |
| occurrences (all) | 18 | 15 | |
| Cardiac disorders | | | |
| Tachycardia | | | |
| subjects affected / exposed | 2 / 38 (5.26%) | 2 / 31 (6.45%) | |
| occurrences (all) | 3 | 2 | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 6 / 38 (15.79%) | 6 / 31 (19.35%) | |
| occurrences (all) | 6 | 8 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 10 / 38 (26.32%) | 15 / 31 (48.39%) | |
| occurrences (all) | 26 | 45 | |
| Lymphopenia | | | |
| subjects affected / exposed | 2 / 38 (5.26%) | 2 / 31 (6.45%) | |
| occurrences (all) | 2 | 7 | |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 38 (0.00%) | 4 / 31 (12.90%) | |
| occurrences (all) | 0 | 6 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 38 (2.63%) | 4 / 31 (12.90%) | |
| occurrences (all) | 3 | 12 | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 25 / 38 (65.79%) | 29 / 31 (93.55%) | |
| occurrences (all) | 66 | 50 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 4 / 38 (10.53%) | 3 / 31 (9.68%) | |
| occurrences (all) | 6 | 8 | |
| Gastrointestinal disorders | | | |

| | | | |
|---|------------------|------------------|--|
| Constipation | | | |
| subjects affected / exposed | 4 / 38 (10.53%) | 4 / 31 (12.90%) | |
| occurrences (all) | 7 | 9 | |
| Diarrhoea | | | |
| subjects affected / exposed | 7 / 38 (18.42%) | 4 / 31 (12.90%) | |
| occurrences (all) | 12 | 12 | |
| Dry mouth | | | |
| subjects affected / exposed | 4 / 38 (10.53%) | 1 / 31 (3.23%) | |
| occurrences (all) | 5 | 1 | |
| Dyspepsia | | | |
| subjects affected / exposed | 7 / 38 (18.42%) | 3 / 31 (9.68%) | |
| occurrences (all) | 13 | 4 | |
| Flatulence | | | |
| subjects affected / exposed | 5 / 38 (13.16%) | 1 / 31 (3.23%) | |
| occurrences (all) | 3 | 1 | |
| Nausea | | | |
| subjects affected / exposed | 11 / 38 (28.95%) | 17 / 31 (54.84%) | |
| occurrences (all) | 21 | 44 | |
| Vomiting | | | |
| subjects affected / exposed | 4 / 38 (10.53%) | 7 / 31 (22.58%) | |
| occurrences (all) | 5 | 17 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Coughing | | | |
| subjects affected / exposed | 22 / 38 (57.89%) | 11 / 31 (35.48%) | |
| occurrences (all) | 47 | 33 | |
| Dyspnoea | | | |
| subjects affected / exposed | 15 / 38 (39.47%) | 13 / 31 (41.94%) | |
| occurrences (all) | 35 | 28 | |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 2 / 38 (5.26%) | 3 / 31 (9.68%) | |
| occurrences (all) | 1 | 3 | |
| Rash | | | |
| subjects affected / exposed | 3 / 38 (7.89%) | 4 / 31 (12.90%) | |
| occurrences (all) | 3 | 10 | |
| Pruritus | | | |

| | | | |
|---|---|---|--|
| subjects affected / exposed occurrences (all) | 2 / 38 (5.26%) 2 | 3 / 31 (9.68%) 10 | |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 6 / 38 (15.79%) 8 | 2 / 31 (6.45%) 9 | |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all) Dizziness subjects affected / exposed occurrences (all) | 2 / 38 (5.26%) 3 8 / 38 (21.05%) 10 3 / 38 (7.89%) 3 | 3 / 31 (9.68%) 4 5 / 31 (16.13%) 6 6 / 31 (19.35%) 6 | |
| Infections and infestations Upper respiratory infection subjects affected / exposed occurrences (all) | 5 / 38 (13.16%) 9 | 4 / 31 (12.90%) 7 | |
| Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all) Hyponatremia subjects affected / exposed occurrences (all) | 12 / 38 (31.58%) 21 2 / 38 (5.26%) 3 | 11 / 31 (35.48%) 22 3 / 31 (9.68%) 3 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported